Efficacy of vortioxetine versus desvenlafaxine in the treatment of functional impairment in patients with major depressive disorder: Results from the multinational VIVRE study
Vortioxetine was significantly better than desvenlafaxine in improving overall functioning as well as daily, social, and cognitive functioning in patients with MDD with inadequate response to prior SSRI therapy.
Authors
- Andreas Rieckmann (ORCID: https://orcid.org/0000-0001-8695-2376)
- Iría Grande (ORCID: https://orcid.org/0000-0002-0137-0666)
- Michael Cronquist Christensen (ORCID: https://orcid.org/0000-0002-3605-7223)
- Pratap Chokka (ORCID: https://orcid.org/0000-0002-1043-8554)
Institutions
- Lundbeck (Denmark) (DK)
- University of Alberta (CA)
- Grey Nuns Community Hospital (CA)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Departament de Salut (ES)
- Hospital Clínic de Barcelona (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- CNS Spectrums
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1017/s1092852924000610
- Citations
- 6
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 2.69
Funders
- H. Lundbeck A/S